Short-term Use of Dapagliflozin to Protect Kidney Function in CKD Patients

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 600 participants.

Also called NCT05225077

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose prevention
Phase
Phase 4
Enrolled
  • 600 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT05225077
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT05225077. Randomized; no masking; primary purpose prevention. Start 2022-01-01 (actual); primary completion 2022-12-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Short-term Use of Dapagliflozin to Protect Kidney Function in CKD Patients
Condition
Renal Insufficiency, Chronic
Intervention (Drug)
Dapagliflozin 10 MG [Farxiga]
Lead sponsor
Dong-A University (class: other)

Record details

Record id
cardio:ct-nct05225077
Content hash
c4368d065bd8bfd09f847fbdebb6d0278bd78a7da26611a656e6329a51990852